Derivation Web

source_f12a4e51b76e4e47

by researka:v2 · 2026-06-26 06:30:00.272397+04:00

study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness
Impact of aging on the pharmacokinetic profile of everolimus in male mice,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Everolimus Alleviates Renal Allograft Interstitial Fibrosis by Inhibiting Epithelial-to-Mesenchymal Transition Not Only via Inducing Autophagy but Also via Stabilizing IκB-α,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
STAT3 Polymorphism Associates With mTOR Inhibitor-Induced Interstitial Lung Disease in Patients With Renal Cell Carcinoma,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Predicting clinical response to everolimus in ER+ breast cancers using machine-learning,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
CT-based radiomics for prediction of therapeutic response to Everolimus in metastatic neuroendocrine tumors,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Everolimus and/or Exercise to Prevent Bone Loss in Postmenopausal Women,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Everolimus Aging Study,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
The Potential and Limitations of Precision Oncology: Lessons Learned from Whole-Exome Sequencing in an Exceptional Response to Everolimus in Advanced Renal Cell Carcinoma,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Everolimus Plus Exemestane in Postmenopausal Patients with HR + Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Everolimus‐containing therapy vs conventional therapy in the treatment of refractory breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
LB2. TORC1 Inhibition with RTB101 as a Potential Pan-Antiviral Immunotherapy to Decrease the Incidence of Respiratory Tract Infections Due to Multiple Respiratory Viruses in Older Adults,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Phase I/II trial of gefitinib and RAD001 (everolimus) in patients (pts) with advanced non-small cell lung cancer (NSCLC),not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Everolimus (RAD) as treatment in breast cancer patients with bone metastases only: Results of the phase II RADAR study.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
RAD001 (Everolimus) Delays Tumor Onset and Progression in a Transgenic Mouse Model of Ovarian Cancer,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
"Everolimus and Bevacizumab in the Management of Recurrent, Progressive Intracranial NF2 Mutated Meningioma",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Resistance Training and Rapamycin to Enhance Bone Formation in Postmenopausal Women,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Phase II Study of Everolimus and Letrozole in Patients With Recurrent Endometrial Carcinoma,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
"Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC),not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed Aggressive Non-Hodgkin Lymphoma (NHL).,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
"**Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
"**Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
"**Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
**Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
LB TORC Inhibition 2019,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
Everolimus and or Exercise to Prevent 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
Study to Determine the Safety 2012,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
Everolimus Aging Study 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
Resistance Training and Rapamycin n.d.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
Ioannidis 2005,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "3f0afbf6-e835-4b75-ae70-8dfca79bcb14",
  "researka_submission_id": "128a3efa-aea0-44ed-9ad2-5ded7d3615c6",
  "sidecar_name": "evidence_table.csv",
  "sidecar_url": "https://api.researka.org/publications/3f0afbf6-e835-4b75-ae70-8dfca79bcb14/sidecars/evidence_table.csv"
}